ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $653,000 | +32550.0% | 15,766 | +74976.2% | 0.02% | – |
| Q4 2021 | $2,000 | -99.7% | 21 | -99.7% | 0.00% | -100.0% |
| Q3 2021 | $712,000 | -26.1% | 7,891 | -21.9% | 0.02% | -25.8% |
| Q2 2021 | $963,000 | +1589.5% | 10,100 | +1368.0% | 0.03% | +416.7% |
| Q3 2020 | $57,000 | +5600.0% | 688 | +3340.0% | 0.01% | – |
| Q3 2019 | $1,000 | 0.0% | 20 | -13.0% | 0.00% | – |
| Q4 2018 | $1,000 | -80.0% | 23 | -65.2% | 0.00% | -100.0% |
| Q3 2018 | $5,000 | -28.6% | 66 | -38.9% | 0.00% | -71.4% |
| Q2 2017 | $7,000 | +600.0% | 108 | +390.9% | 0.01% | +600.0% |
| Q1 2017 | $1,000 | – | 22 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |